BioCentury
ARTICLE | Company News

Chiron, Pharmacia & Upjohn deal

February 9, 1998 8:00 AM UTC

The companies will identify small molecule inhibitors of the hepatitis C virus. The deal will combine CHIR’s HCV virology, protein expression, high throughput assay development and combinatorial chemistry capabilities with P&U’s structural biology, medicinal chemistry and preclinical expertise. P&U will make an upfront payment to CHIR. Each company will contribute equal resources to the project and will equally share worldwide marketing rights. P&U received non-exclusive rights to all HCV targets covered by CHIR's patents. ...